Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial...
Main Authors: | David J. Benjamin, Robert Hsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258388/full |
Similar Items
-
Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
by: Xinyi Zheng, et al.
Published: (2023-01-01) -
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
by: Anuhya Kommalapati, et al.
Published: (2021-06-01) -
Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment
by: Songbai Wang, et al.
Published: (2020-07-01) -
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01) -
Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma
by: Katherine A. Lawson‐Michod, et al.
Published: (2022-10-01)